Medical Xpress - Cardiology

APRIL 4, 2024

Diabetic cardiomyopathy (DC) is a serious condition characterized by impaired heart function due to diabetes-related metabolic abnormalities. Diabetes is a global health burden. A whopping 536 million people worldwide struggle with diabetes.

Cardiomyopathy 115

Cardiomyopathy Diabetes 115

Nature Reviews - Cardiology

SEPTEMBER 18, 2024

Nature Reviews Cardiology, Published online: 19 September 2024; doi:10.1038/s41569-024-01086-y Data from the HELIOS-B trial show that RNA interference with vutrisiran reduces the risk of death and recurrent cardiovascular events in patients with transthyretin amyloidosis with cardiomyopathy.

Cardiomyopathy 40

Cardiomyopathy 40

Frontiers in Cardiovascular Medicine

DECEMBER 18, 2023

Background Chagas cardiomyopathy (CHCM) is the most important clinical manifestation of Chagas disease. The analysis of cardiac miRNAs may contribute to predicting the progression to CHCM in Chagas indeterminate phase and/or to the differential diagnosis for cardiomyopathy.

Circulation 84

Circulation Cardiomyopathy Biomarkers Laboratory 84

The New England Journal of Medicine

JANUARY 10, 2024

The author discusses the epidemiology and clinical presentation of peripartum cardiomyopathy, as well as the mechanistic basis for potential therapeutics.

Cardiomyopathy 75

Cardiomyopathy 75

Science Daily - Heart Disease

MAY 8, 2024

Experts released a new clinical guideline for effectively managing individuals diagnosed with hypertrophic cardiomyopathy (HCM). The guideline reiterates the importance of collaborative decision-making with patients who have HCM and provides updated recommendations for the most effective treatment pathways for adult and pediatric patients.

Cardiomyopathy 93

Cardiomyopathy Exercise Pediatrics 93

American College of Cardiology

JUNE 3, 2024

The following are key points to remember from a state-of-the-art review on arrhythmia-induced cardiomyopathy (AiCM).

Arrhythmia 75

Arrhythmia Cardiomyopathy Article 75

All About Cardiovascular System and Disorders

FEBRUARY 24, 2024

Arrhythmogenic Cardiomyopathy was better known as Arrhythmogenic Right Ventricular Dysplasia or ARVD and sometimes as Arrhythmogenic Right Ventricular Cardiomyopathy or ARVC earlier. A study published in JACC has compared the phenotypic expression and clinical outcomes in patients with arrhythmogenic cardiomyopathy [2].

Cardiomyopathy 52

Cardiomyopathy Chest Pain Heart Transplant Myocardial Infarction 52

Cardiovascular Diabetology

SEPTEMBER 11, 2024

Nonischemic cardiomyopathy (NISCM) is a clinical challenge with limited therapeutic targets. This study aims to identify promising drug targets for NISCM.

Cardiomyopathy 52

Cardiomyopathy Research 52

All About Cardiovascular System and Disorders

DECEMBER 15, 2023

Idiopathic dilated cardiomyopathy Idiopathic dilated cardiomyopathy is a form of dilated cardiomyopathy with unknown etiology characterised by progressive left ventricular dilatation and systolic dysfunction. The incidence of idiopathic dilated cardiomyopathy varies from 3-10 cases per 100,000 population.

Cardiomyopathy 52

Cardiomyopathy General Cardiology 52

Frontiers in Cardiovascular Medicine

JUNE 28, 2024

Septic cardiomyopathy, a life-threatening complication of sepsis, can cause acute heart failure and carry a high mortality risk. These exosomes can both diagnose and treat septic cardiomyopathy, playing a crucial role in its development and progression. Current treatments have limitations.

Cardiomyopathy 52

Cardiomyopathy Article Technology Cardiac Function 52

Medical Xpress - Cardiology

SEPTEMBER 2, 2024

An international cardiology working group has published a consensus report on atrial cardiomyopathy in Europace.

Document 61

Document Cardiomyopathy Heart Rhythm 61

Frontiers in Cardiovascular Medicine

FEBRUARY 23, 2024

Infiltration of the myocardium with various cell types, cytokines and chemokines plays a crucial role in the pathogenesis of cardiomyopathies including inflammatory cardiomyopathies and myocarditis. This review offers a comprehensive overview of the current knowledge of the immune landscape in cardiomyopathies based on etiology.

Cardiomyopathy 81

Cardiomyopathy 81

Medical Xpress - Cardiology

JANUARY 14, 2024

Acoramidis yields a significantly better four-step primary hierarchical outcome, including aspects of mortality and morbidity, than placebo for patients with transthyretin amyloid cardiomyopathy, according to a study published in the Jan. 11 issue of the New England Journal of Medicine.

Cardiomyopathy 85

Cardiomyopathy Outcomes 85

HCPLive

APRIL 10, 2024

A trio of experts discuss their perspectives on the recent advancement in pharmacotherapy within the management of hypertrophic cardiomyopathy.

Cardiomyopathy 78

Cardiomyopathy 78

Cardiovascular Diabetology

JUNE 28, 2024

Diabetic cardiomyopathy (DCM) is characterized by cardiomyocyte hypertrophy, myocardial fibrosis. In recent years, the incidence of diabetes has been increasing rapidly, posing a serious threat to human health.

Cardiomyopathy 59

Cardiomyopathy Diabetes 59

Frontiers in Cardiovascular Medicine

MARCH 19, 2024

Background Precision medicine in paediatric cardiac channelopathy and cardiomyopathy has a rapid advancement over the past years. Results A total of 31 patients (11 cardiac channelopathy and 20 cardiomyopathy) were recruited. Results A total of 31 patients (11 cardiac channelopathy and 20 cardiomyopathy) were recruited.

Cardiomyopathy 64

Cardiomyopathy 64

Frontiers in Cardiovascular Medicine

MARCH 6, 2024

Cardiomyopathy, a heterogeneous pathological condition characterized by changes in cardiac structure or function, represents a significant risk factor for the prevalence and mortality of cardiovascular disease (CVD). Research conducted over the years has led to the modification of definition and classification of cardiomyopathy.

Cardiomyopathy 59

Cardiomyopathy Diabetes Obesity Risk Factors 59

American College of Cardiology

JULY 12, 2024

What are the racial and ethnic differences among individuals with diabetic dilated cardiomyopathy at high risk for overt heart failure?

Cardiomyopathy 56

Cardiomyopathy Diabetes Heart Failure Article 56

American College of Cardiology

APRIL 17, 2024

What is the risk of mortality and composite cardiomyopathy-related outcomes associated with predicted deleterious variants in cardiomyopathy-associated genes?

Cardiomyopathy 56

Cardiomyopathy Outcomes Article 56

Nature Reviews - Cardiology

MAY 27, 2024

Nature Reviews Cardiology, Published online: 28 May 2024; doi:10.1038/s41569-024-01044-8 Data from the SEQUOIA-HCM trial show that aficamten, a cardiac myosin inhibitor, increases exercise capacity and improves quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cardiomyopathy 64

Cardiomyopathy Quality of Life Exercise 64

American College of Cardiology

JULY 15, 2024

The following are key points to remember from an article about genetics of hypertrophic cardiomyopathy (HCM), which reviews established and emerging implications for clinical practice.

Cardiomyopathy 49

Cardiomyopathy Article 49

Circulation

DECEMBER 21, 2023

microRNAs translocate into subcellular organelles to modify genes involved in diabetic cardiomyopathy. Malonylation, a posttranslational modification of Ago2, reduced the importing of Ago2 into mitochondria in diabetic cardiomyopathy. BACKGROUND:Diabetes is associated with cardiovascular complications.

Cardiomyopathy 81

Cardiomyopathy Diabetes Circulation 81

Frontiers in Cardiovascular Medicine

MARCH 24, 2024

Diabetic cardiomyopathy (DCM), one of the most serious complications of diabetes mellitus, has become recognized as a cardiometabolic disease. The shift in energy substrate preference in diabetic hearts results in increased oxygen consumption and impaired oxidative phosphorylation, leading to diabetic cardiomyopathy.

Cardiomyopathy 64

Cardiomyopathy Diabetes 64

American College of Cardiology

AUGUST 30, 2024

The goal of the HELIOS-B trial was to evaluate vutrisiran compared with placebo among patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).

Cardiomyopathy 49

Cardiomyopathy Article 49

American College of Cardiology

MAY 2, 2024

What is the prognostic value of extent of late gadolinium enhancement (LGE) in predicting sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM)?

Sudden Cardiac Death 65

Sudden Cardiac Death Cardiomyopathy Article 65

Frontiers in Cardiovascular Medicine

JULY 11, 2024

BackgroundDilated cardiomyopathy (DCM) is a heterogeneous myocardial disorder with diverse genetic or acquired origins. Notable advances have been achieved in discovering and understanding the genetics of DCM.

Cardiomyopathy 52

Cardiomyopathy Research Sudden Cardiac Death Document 52

The American Journal of Cardiology

JANUARY 30, 2024

Hypertrophic cardiomyopathy (HCM) is a heterogeneous genetic heart disease inherited in an autosomal dominant pattern with an estimated prevalence of …

Cardiomyopathy 71

Cardiomyopathy Heart Disease 71

Heart BMJ

JULY 10, 2024

1 Early ERT treatment cohorts included many patients with high disease load, including advanced cardiomyopathy and nephropathy. Prognosis has improved, but cardiomyopathy remains the life-limiting complication of Fabry disease for most patients.

Cardiomyopathy 52

Cardiomyopathy 52

Frontiers in Cardiovascular Medicine

JULY 5, 2024

BackgroundThe alpha-protein kinase 3 (ALPK3) gene (OMIM: 617608) is associated with autosomal recessive familial hypertrophic cardiomyopathy-27 (CMH27, OMIM: 618052). ConclusionsWe suggest that ALPK3 PTV carriers be considered a risk group for developing HCMP and be monitored for cardiomyopathies.

Cardiomyopathy 52

Cardiomyopathy 52

American College of Cardiology

JULY 2, 2024

What is the effect of AT-001, an aldose reductase inhibitor, on exercise capacity among individuals with diabetic cardiomyopathy (DbCM) with reduced exercise capacity and at high risk for progression to overt heart failure (HF)?

Cardiomyopathy 53

Cardiomyopathy Diabetes Exercise Heart Failure 53

Frontiers in Cardiovascular Medicine

JANUARY 7, 2024

Methods We prospectively enrolled consecutive patients with ischaemic (ICM) and dilated (DCM) cardiomyopathy from the outpatient heart failure clinic and healthy individuals. Plasma SN levels were significantly higher in the dilated cardiomyopathy (38.8 ± 27 pmol/L) as compared with the ischaemic cardiomyopathy (19.7 ± 22.6 pmol/L)

Cardiomyopathy 59

Cardiomyopathy Heart Failure Outpatient Biomarkers 59

Nature Reviews - Cardiology

MAY 19, 2024

Nature Reviews Cardiology, Published online: 20 May 2024; doi:10.1038/s41569-024-01040-y Activation of the bile acid receptor TGR5 inhibits CD36-mediated fatty acid uptake in cardiomyocytes and protects against cardiac lipotoxicity and the development of diabetic cardiomyopathy in mice, according to a new study.

Cardiomyopathy 52

Cardiomyopathy Diabetes 52

Circulation: Genomic and Precision Medicine

JANUARY 30, 2024

TheRBM20gene was first identified as a dilated cardiomyopathy–linked gene over a decade ago. Clinical studies show that pathogenic variants inRBM20are linked to aggressive dilated cardiomyopathy with early onset heart failure and high mortality. Potential therapeutic strategies to treat RBM20 cardiomyopathy are also discussed.

Cardiomyopathy 58

Cardiomyopathy Heart Failure Circulation 58

Heart BMJ

JUNE 17, 2024

Objective Marfan syndrome (MFS)-associated cardiomyopathy, defined as ventricular dilation and dysfunction unexplained by volume loading, is not well defined in children. Conclusion Ventricular dilation and reduced EF are common in children with MFS and occur with no/mild LV volume load, suggesting intrinsic cardiomyopathy.

Cardiomyopathy 52

Cardiomyopathy Bicuspid/Mitral Aortic Strokes 52

The New England Journal of Medicine

JANUARY 10, 2024

In patients with transthyretin amyloid cardiomyopathy, the TTR stabilizer acoramidis resulted in a better primary hierarchical outcome (including mortality, morbidity, and function) than placebo.

Cardiomyopathy 75

Cardiomyopathy Outcomes 75

American College of Cardiology

APRIL 24, 2024

What is the penetrance of new dilated cardiomyopathy (DCM) diagnosis in genotype positive (G+) relatives and the factors associated with DCM development?

Cardiomyopathy 53

Cardiomyopathy Article 53

DAIC

MARCH 6, 2024

Food and Drug Administration’s ( FDA ) Breakthrough Device Designation for their ECGvision-TTR Technology for early detection of ATTR-Cardiomyopathy. ECGvision-TTR was developed through state-of-the-art deep learning algorithms and offers the unique ability to analyze 12-lead ECG images to detect signatures of ATTR Cardiomyopathy.

Technology 105

Technology Cardiomyopathy Quality of Life Innovation 105